Biogen Director Acquires 3,160 Shares in Latest Insider Transaction
Biogen Inc. (BIIB) Director Caroline Dorsa reported acquiring 3,160 shares of Common Stock on June 17, 2025.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Biogen Inc. (BIIB) Director Caroline Dorsa reported acquiring 3,160 shares of Common Stock on June 17, 2025. The shares were awarded at a price of $0, suggesting this was a stock grant as part of director compensation.
Following this transaction, Dorsa now beneficially owns a total of 31,002 shares directly. The filing indicates this was a straightforward acquisition with no derivative securities involved in the transaction.
The Form 4 was signed by Wendell Taylor as attorney-in-fact for Caroline Dorsa on June 18, 2025, within the required reporting timeline. This transaction appears to be part of regular director compensation practices rather than open market trading activity.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Common Stock | 3,160 | $0.00 | $0.00 |
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What is Caroline Dorsa's total BIIB stock ownership after the June 2025 transaction?
What is Caroline Dorsa's role at BIIB according to the Form 4?
When was the Form 4 for BIIB insider trading signed?
AI-generated analysis. How Rhea-AI works. Not financial advice.